JP2020537540A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537540A5 JP2020537540A5 JP2020539688A JP2020539688A JP2020537540A5 JP 2020537540 A5 JP2020537540 A5 JP 2020537540A5 JP 2020539688 A JP2020539688 A JP 2020539688A JP 2020539688 A JP2020539688 A JP 2020539688A JP 2020537540 A5 JP2020537540 A5 JP 2020537540A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sequence
- processing
- crrna
- acid according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000039446 nucleic acids Human genes 0.000 claims 30
- 108020004707 nucleic acids Proteins 0.000 claims 30
- 150000007523 nucleic acids Chemical class 0.000 claims 30
- 125000003729 nucleotide group Chemical group 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108090001008 Avidin Proteins 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024076160A JP2024116119A (ja) | 2017-10-02 | 2024-05-08 | 改変ｃｐｆ１ガイドｒｎａ |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762567123P | 2017-10-02 | 2017-10-02 | |
| US62/567,123 | 2017-10-02 | ||
| US201862617138P | 2018-01-12 | 2018-01-12 | |
| US62/617,138 | 2018-01-12 | ||
| US201862697327P | 2018-07-12 | 2018-07-12 | |
| US62/697,327 | 2018-07-12 | ||
| PCT/US2018/054027 WO2019070762A1 (en) | 2017-10-02 | 2018-10-02 | RNA GUIDE CPF1 MODIFIED |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076160A Division JP2024116119A (ja) | 2017-10-02 | 2024-05-08 | 改変ｃｐｆ１ガイドｒｎａ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020537540A JP2020537540A (ja) | 2020-12-24 |
| JP2020537540A5 true JP2020537540A5 (cg-RX-API-DMAC7.html) | 2021-11-11 |
Family
ID=64184173
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020539688A Pending JP2020537540A (ja) | 2017-10-02 | 2018-10-02 | 改変ｃｐｆ１ガイドｒｎａ |
| JP2024076160A Pending JP2024116119A (ja) | 2017-10-02 | 2024-05-08 | 改変ｃｐｆ１ガイドｒｎａ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024076160A Pending JP2024116119A (ja) | 2017-10-02 | 2024-05-08 | 改変ｃｐｆ１ガイドｒｎａ |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200299689A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3692154A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020537540A (cg-RX-API-DMAC7.html) |
| CN (2) | CN111770994B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018345683B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020006601A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3077189A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL273595B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2020003339A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202003083PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019070762A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170184A1 (en) | 2017-03-14 | 2018-09-20 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| WO2018209158A2 (en) | 2017-05-10 | 2018-11-15 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| US11268092B2 (en) | 2018-01-12 | 2022-03-08 | GenEdit, Inc. | Structure-engineered guide RNA |
| WO2019178426A1 (en) * | 2018-03-14 | 2019-09-19 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
| CA3104856A1 (en) | 2018-06-29 | 2020-01-02 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| GB201905651D0 (en) * | 2019-04-24 | 2019-06-05 | Lightbio Ltd | Nucleic acid constructs and methods for their manufacture |
| GB201913997D0 (en) * | 2019-09-27 | 2019-11-13 | Oxford Nanopore Tech Ltd | Method |
| WO2021127594A1 (en) * | 2019-12-18 | 2021-06-24 | Editas Medicine, Inc. | Engineered cells for therapy |
| CN113234701B (zh) * | 2020-10-20 | 2022-08-16 | 珠海舒桐医疗科技有限公司 | 一种Cpf1蛋白及基因编辑系统 |
| WO2022125329A1 (en) * | 2020-12-07 | 2022-06-16 | Inscripta, Inc. | gRNA STABILIZATION IN NUCLEIC ACID-GUIDED NICKASE EDITING |
| WO2023201270A2 (en) * | 2022-04-13 | 2023-10-19 | Caribou Biosciences, Inc. | Therapeutic applications of crispr type v systems |
| US20240167029A1 (en) * | 2022-06-27 | 2024-05-23 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2025212120A1 (en) * | 2024-04-05 | 2025-10-09 | Arbor Biotechnologies, Inc. | Chemical modifications of guide rnas for crispr nucleases |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| DK3350327T3 (en) * | 2015-10-23 | 2019-01-21 | Caribou Biosciences Inc | CONSTRUCTED CRISPR CLASS-2-NUCLEIC ACID TARGETING-NUCLEIC ACID |
| CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
| CA3062165A1 (en) * | 2017-05-04 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for gene editing in t cells using crispr/cpf1 |
-
2018
- 2018-10-02 IL IL273595A patent/IL273595B1/en unknown
- 2018-10-02 CA CA3077189A patent/CA3077189A1/en active Pending
- 2018-10-02 CN CN201880077637.7A patent/CN111770994B/zh active Active
- 2018-10-02 CN CN202510240123.0A patent/CN120290559A/zh active Pending
- 2018-10-02 JP JP2020539688A patent/JP2020537540A/ja active Pending
- 2018-10-02 WO PCT/US2018/054027 patent/WO2019070762A1/en not_active Ceased
- 2018-10-02 BR BR112020006601-0A patent/BR112020006601A2/pt unknown
- 2018-10-02 EP EP18799900.8A patent/EP3692154A1/en active Pending
- 2018-10-02 AU AU2018345683A patent/AU2018345683B2/en active Active
- 2018-10-02 MX MX2020003339A patent/MX2020003339A/es unknown
- 2018-10-02 US US16/753,293 patent/US20200299689A1/en active Pending
- 2018-10-02 SG SG11202003083PA patent/SG11202003083PA/en unknown
-
2024
- 2024-05-08 JP JP2024076160A patent/JP2024116119A/ja active Pending
-
2025
- 2025-04-11 AU AU2025202594A patent/AU2025202594A1/en active Pending
- 2025-09-10 IL IL323269A patent/IL323269A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537540A5 (cg-RX-API-DMAC7.html) | ||
| JP7672445B2 (ja) | ＣａｓＺ組成物及び使用方法 | |
| JP7698828B2 (ja) | Ｒｎａを編集する方法および組成物 | |
| ES2962434T3 (es) | Procedimientos y composiciones para editar ARN | |
| Wang et al. | Chemically modified DNA nanostructures for drug delivery | |
| Khisamutdinov et al. | RNA as a boiling-resistant anionic polymer material to build robust structures with defined shape and stoichiometry | |
| Li et al. | Smart drug delivery nanocarriers with self‐assembled DNA nanostructures | |
| Kwak et al. | Nucleic acid/organic polymer hybrid materials: synthesis, superstructures, and applications | |
| ES2743188T3 (es) | Péptidos y nanopartículas para el suministro intracelular de moléculas | |
| Jasinski et al. | Physicochemically tunable polyfunctionalized RNA square architecture with fluorogenic and ribozymatic properties | |
| Alemdaroglu et al. | DNA meets synthetic polymers—highly versatile hybrid materials | |
| Ruff et al. | Precision templating with DNA of a virus-like particle with peptide nanostructures | |
| Chen et al. | Nuclear actin and actin-related proteins in chromatin dynamics | |
| JP2019528284A5 (cg-RX-API-DMAC7.html) | ||
| JP2018518181A5 (cg-RX-API-DMAC7.html) | ||
| Huang et al. | Self-assembled DNA nanostructures-based nanocarriers enabled functional nucleic acids delivery | |
| JP2007504830A5 (cg-RX-API-DMAC7.html) | ||
| JP2019517268A (ja) | 化学的に修飾されたガイドｒｎａを使用する高特異性ゲノム編集 | |
| JP2017510542A5 (cg-RX-API-DMAC7.html) | ||
| JP2016521554A5 (cg-RX-API-DMAC7.html) | ||
| WO2017143042A3 (en) | Compositions for enhancing targeted gene editing and methods of use thereof | |
| CN107354173A (zh) | 基于crispr技术和水动力尾静脉注射建立肝脏特异性敲除小鼠模型的方法 | |
| AU2002214596A1 (en) | Methods and compositions for nucleic acid delivery | |
| Finke et al. | Designer extracellular matrix based on DNA–peptide networks generated by polymerase chain reaction | |
| Bi et al. | Self-assembled multifunctional DNA nanospheres for biosensing and drug delivery into specific target cells |